Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-10-31
2006-10-31
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C530S350000, C424S184100, C424S185100
Reexamination Certificate
active
07128918
ABSTRACT:
Streptococcusproteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofstreptococcusinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingstreptococcusbacterial infection.
REFERENCES:
patent: 6503511 (2003-01-01), Wizemann et al.
patent: 6582706 (2003-06-01), Johnson et al.
patent: 6800744 (2004-10-01), Doucette-Stamm et al.
patent: 6833356 (2004-12-01), Koenig et al.
patent: 2003/0077293 (2003-04-01), Hamel et al.
patent: 2003/0138447 (2003-07-01), Wizemann et al.
patent: 2003/0232976 (2003-12-01), Hamel et al.
patent: 2004/0001836 (2004-01-01), Johnson et al.
patent: 2004/0005331 (2004-01-01), Johnson et al.
patent: 2004/0052781 (2004-03-01), Johnson et al.
patent: 2004/0081662 (2004-04-01), Hermand et al.
patent: 98/18930 (1998-05-01), None
patent: 98/18931 (1998-05-01), None
patent: WO 99/15675 (1999-04-01), None
patent: WO 00/06737 (2000-02-01), None
patent: WO 00/06738 (2000-02-01), None
patent: WO 00/17370 (2000-03-01), None
patent: 00/37105 (2000-06-01), None
patent: WO00/39299 (2000-07-01), None
patent: 00/76540 (2000-12-01), None
patent: 01/14421 (2001-03-01), None
patent: WO01/98334 (2001-12-01), None
patent: WO02/077021 (2002-10-01), None
patent: WO04/092209 (2004-10-01), None
Boslego, John W. et al, Chapter 17, pp. 211-223, Vaccines and Immunotherapy, Pergamon Press, 1991.
Ellis, Ronald W. Ph.D. Chapter 29, New Technologies for Making Vaccines, Vaccines, WB Saunders Co., 1988, pp. 568-575.
Adamou, John E et al, Infection and Immunity, Feb. 2001, vol. 69(2), pp. 949-958, Identification and characterization of a Novel Family ofPneumococcalproteins that are protective against sepsis.
Swiss Prot Accession No. Q9ANY1—Strpn.
Boslego et al. Chapter 17: ‘Gonorrhea Vaccines’, “Vaccines And Immunotherapy”. Pergamon Press, 1991, pp. 211-223.
Ellis, et al. Chapter 29: ‘New Technologies for Making Vaccines’, “Vaccines”. WB Sanders Co., 1988, Chapter 29, pp. 568-575.
“Lmb, a Protein with Similarities to the LraI Adhesin Family, Mediates Attachment ofStreptococcus agelactiaeto Human Laminin”, by R. Spellerberg, et al., Infection and Immunity, vol. 67, No. 2, Feb. 1999, pp. 871-878.
PCT Notification of Transmittal of The International Search Report or The Declaration dated Jul. 24, 2000.
Orihuela, et al., “Organ-Sepcific models ofStreptococcus pneumoniaeDisease,” Scandinavian Journal of Infectious Diseases, vol. 35, No. 9, 2003, p. 647-652.
Whittam, et al., “Inferences from whole-genome sequences of bacterial pathogensm,” Current Opinion in Genetics and Development, Dec. 2002, vol. 12, No. 6, pp. 719-725.
Sa-Leao, et al., Abstracts of the General Meeting of the American Society for Microbiology, May 20-24, 2001.
Creighton, Thomas E. in his book, “Proteins: Structures and Molecular Principles,” 1984, pp. 314-315.
Creighton, Thomas E. in his book, “Protein Structure: A Practical Approach,” 1989; pp. 184-186.
Nosoh, et al., in “Protein Stability and Stabilization through Protein Engineering,” 1991, pp. 197-217.
Oli, et al., “Redirecting the Humoral Immune Response againstStreptococcusmutans Antigen P1 with Monoclonal Antibodies,” Infection and Immunity, Dec. 2004, p. 6951-6960.
Swildens, et al., “Intestinal translocation ofStreptococcus suistype 2EF* in pigs,” Veterinary Microbiology 103, 2004, pp. 29-33.
Bolton, et al., “Use of the surface proteins GapC and Mig ofStreptococcus dysgalactiaeas potential protective antigens against bovine mastitis,” Can J. Microbiol., Jun. 2004, 50(6):423-32 (Abstract only).
Okamoto, et al., “Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenzaStreptococcus pyogenessuperinfection,” Vaccine 22, 2004, pp. 2887-2893.
Briles, et al., “Immunization of Humans with RecombinantPneumococcalSurface Protein A (rPspA) Elicits Antibodies that Passively Protect Mice from Fatal Infection withStreptococcus pneumoniaebearing Heterologous PsPA”, J. Infectious Disease. 182, Dec. 2000, pp. 1694-1701.
Briles, et al., “Intranasal Immunization of Mice with a Mixture of thePneumococcalProteins PsaA and PspA is Highly Protective against Nasopharyngeal Carriage ofStreptococcus pneumoniae”, Infection & Immunity, vol. 68, No. 2, Feb. 2000, pp. 796-800.
Zysk, et al, “Detection of 23 ImmunogenicPneumococcalProteins Using Convalescent-Phase Serum”, Infection & Immunity, vol. 68, No. 6, Jun. 2000, pp. 3740-3743.
Spellerberg, et al., “Lmb, a Protein with Similarities to the Lral Adhesin Family, Mediates Attachment ofStreptococcus agalactiaeto Human Laminin”, Infection and Immunity, Feb. 1999, pp. 871-878.
Adamou, et al., “Identification and Characterization of a Novel Family ofPneumococcalProteins that are Protective Against Sepsis”. Infection and Immunity, Feb. 2001, pp. 949-958.
Wizemann, et al., “Use of a Whole Genome Approach to Identify Vaccine Molecules Affording Protection AgainstStreptococcus pneumoniaeInfection”, Infection and Immunity, Mar. 2001, pp. 1593-1598.
Zhang, et al., “Recominant PhpA Protein, a Unique Histidine Motif-Containing Protein fromStreptococcus pneumoniae, Protects Mice against IntranasalPneumococcalChallenge”, Infection and Immunity, Jun. 2001, pp. 3827-3838.
Hernandez, et al., “Antigenicity of Chimeric Synthetic Peptides Based on HTLV-1 Antigens and the Impact of Epitope Orientation.” Biochemical and Biophysical Research Communications, vol. 278, No. 3, pp. 1085-1088.
Partidos et al., “The Influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides.” Eur. J. Immunol 1992, 22: pp. 2675-2680.
Oishi, et al., “The effect of amino acid spacers on the antigenicity of dimeric peptide-inducing cross-reacting antibodies to a cell surface protein antigen ofStreptococcusmutans.” Oral Microbiol Immunol 2001: 16: pp. 40-44.
Kurstak, Edward, “Editorial Recent progress in vaccines development and new trends in immunisation.” Vaccine 19 (2001) pp. 2198-2200.
Brodeur Bernard R.
Charland Nathalie
Hamel Josee
Martin Denis
Pineau Isabelle
ID Biomedical Corporation
Portner Ginny Allen
Smith Lynette R. F.
LandOfFree
Streptococcus antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcus antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcus antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3684416